Question of the Day – Thursday January 19, 2017
Question: MEK inhibitors (inhibit the mitogen- activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) kinase) are a relatively new class of chemotherapeutic agents used in the treatment of a variety of metastatic cancers. These agents have been associated with the development of ocular toxicity. What is the nature of this toxicity?
Question of the Day – Wednesday January 18, 2017
Question: What is the elimination half-life of smoked crystal methamphetamine?
Question of the Day – Tuesday January 17, 2017
Question: How do electronic cigarettes produce the vapor inhaled by users of these products?
Question of the Day – Monday January 16, 2017
Question: Lithium is widely used as long-term therapy for bipolar disorder. What are the clinically important adverse risks for patients on long-term lithium therapy?
Question of the Day – Friday January 13, 2017
Question: What does the term “signal word”, as used by U.S. EPA, signify?
Question of the Day – Wednesday January 11, 2017
Question: Which foodborne pathogen accounts for approximately 20 percent of bacterial meningitis in individuals older than 60 years of age and has been associated with unpasteurized milk and soft cheese ingestion?
Question of the Day – Tuesday January 10, 2017
Question: A variety of clinical forms of botulism have been recognized. These include wound botulism, food borne botulism, and infant botulism. What is the most common form of botulism reported in the United States?
Question of the Day – Monday January 9, 2017
Question: Botulism is an uncommon disorder caused by toxins produced by Clostridium botulinum. Seven subtypes of botulinum toxin exist (subtypes A, B, C, D, E, F and G). Which subtypes have been noted to cause human disease and which ones have been reported to cause infant botulism specifically in the United States?
Question of the Day – Friday January 6, 2017
Question: What are the reported central nervous system manifestations associated with neonatal abstinence syndrome?